Company: LNAI
Filing Date: 2025-05-15
Form Type: 10-Q
Source: 0001731122-25-000765
Chunk: 85

Company: Lunai Bioworks Inc.
Filing Date: 2025-05-15
Form: 10-Q
Item: Part I, Item 8
Chunk 85
---
 Concurrently with entering into the
2023 Purchase Agreement, the Company also entered into a registration rights agreement with Lincoln Park, pursuant to which it agreed
to provide Lincoln Park with certain registration rights related to the shares issued under the 2023 Purchase Agreement.

In consideration for entering into
the 2023 Purchase Agreement, the Company issued 696,021 shares of Common Stock to Lincoln Park as a commitment fee on June 20, 2023.

During the quarter ended March
31, 2025 and 2024, no shares of Common Stock to Lincoln Park were sold under the Purchase Agreement.

Common Stock Issuances 

On June
14, 2024, Renovaro Inc., a Delaware corporation (the “Company”) closed a private placement of 5,315,215 of
the Company’s units, each such Unit consisting of (i) one share of the Company’s Common Stock and (ii) one common stock purchase
warrant to purchase one-tenth of a share of Common Stock, with certain investors (the “June 2024 Private Placement”). Related
to the June 2024 Private Placement, ranging from July 3, 2024, to October 10, 2024, the Company sold 1,613,596 Units at a price per Unit
equal to $1.4726 to a certain investor who paid in cash an aggregate amount of $2,376,181 in consideration of the Units.

On August 1, 2024, the Company
issued 2,000,000 shares of Common Stock for consulting services valued at $1,400,000.

On October 14, 2024, the Company
issued 250,000 shares of Common Stock to its Chief Executive Officer valued at $137,500.

On October 14, 2024, the Company
issued 500,000 shares of Common Stock for consulting services valued at $275,000.

On October 17, 2024, the Company
issued 160,000 shares of Common Stock for consulting services valued at $118,400.

    14

On January 21, 2025, the Company
issued 250,000 shares of Common Stock to its Chief Executive Officer of Renovaro Cube valued at $177,500.

Beginning February 24, 2025, the Company entered into a public equity offering.
(see Note 7 – Commitment and Contingencies). 

Stock-based